There are numerous methodologies available for the analysis of genomic CFTR DNA. We present here the basic tools to allow a thorough investigation of the CFTR gene, beginning with the identification of potential regulatory regions using DNase I hypersensitive sites, and continuing with methods for the detection of mutations: denaturing High Performance Liquid Chromatography (dHPLC), Single Strand Conformation Polymorphism (SSCP), and allele-specific oligonucleotide (ASO) hybridisation. Also provided is a comprehensive set of PCR primers for the amplification of most regions of the CFTR gene. Full details of the methodologies given are to be found at the European Working Group on CFTR Expression website
Introduction
There are numerous methodologies at the disposal of the molecular geneticist for the analysis of genomic CFTR DNA. We present here the basic tools to allow a thorough investigation of the CFTR gene and the development of a strategy for the identification of all sequence changes in the CFTR gene. Beginning with the identification of potential regulatory regions using DNase I hypersensitive sites, we then describe three different protocols for the detection of mutations: denaturing High Performance Liquid Chromatography (dHPLC), Single Strand Conformation Polymorphism (SSCP), and allele-specific oligonucleotide (ASO) hybridisation. Also provided is a comprehensive set of PCR primers that can be used for the amplification of most regions of the CFTR gene. Full details of the methodologies given are to be found in the found at the European Working Group on CFTR Expression website [1] .
Identification of potential regulatory elements

Assay for DNase I hypersensitive sites in chromatin
This protocol describes the extraction of chromatin from tissues and cells to subsequently map and evaluate DNase I hypersensitive sites that are often associated with regulatory elements in a gene. The method of extraction of chromatin from tissues is adapted from Becker et al. [2] . The extraction of chromatin from cells was adapted from Higgs et al. [3] . The whole procedure has to be performed at 4 jC. Tissue is roughly mashed and added to buffer A (mM): 60 KCl; 15 NaCl; 15; Tris pH 7.5, 500 sucrose; 0.5 EGTA; 2 EDTA; 0.5 spermidine; 0.15 spermine; 0.5 hmercaptoethanol; 5 DTT; 1 phenyl methyl sulfonyl fluoride, PMSF (10 ml/g of tissue). Spermidine, spermine, hmercaptoethanol, DTT and PMSF are added just before use. The tissue is then homogenized and filtered 2 Â through sterile gauzes. The volume is then adjusted to 50 ml with buffer A and the suspension is centrifuged at 3000 Â g for 10 min at 4 jC. The pellet is resuspended in 5 ml of buffer A and the cells lysed by adding 5 ml of buffer A containing 0.8% (v/v) triton X100. The resulting suspension is then mixed and incubated on ice for 10 min. This is then centrifuged at 3000 Â g for 15 min at 4 jC and the resultant pellet resuspended in 10 ml of buffer A. This wash is repeated three times, before filtering through a 70 Am cell strainer. The product is then centrifuged at 1000 Â g for 10 min at 4 jC, and the pellet resuspended in 50 ml of RBS (mM): 10 Tris HCl pH 7.5; 10 NaCl; 3 MgCl 2 . This is then centrifuged at 1000 Â g for 10 min at 4 jC and the pellet resuspended in 0.8 ml of RSB, before proceeding to DNase I digestion of samples.
To DNase I (Amersham Pharmacia, Little Chalfont, UK, cat no.: 27-0514-02) is used for digestion. One tube with no DNase I remains at 4 jC, and a second tube with no DNase I is incubated at 37 jC as a control for any endogenous DNase I activity. The remaining four tubes that contain increasing amount of DNase I are incubated at 37 jC (about 20 min) until the penultimate tube is clear (not viscous) when mixed with 50 Al of lysis buffer (10 mM Tris HCl pH 8.0; 10 mM NaCl; 10 mM EDTA pH 8; 0.5% (w/v) SDS). 1 ml of lysis buffer is added to the remaining samples to stop the reaction. DNase I digestion may also be carried out with the same amount of enzyme in each tube but increasing incubation times. 10 Al of proteinase K (50 mg/ml) is added to each sample and incubated at 37 jC overnight. If the DNA solution is still viscous, more proteinase K is added and incubated until the solution is no longer viscous. After one phenol/chloroform extraction and two chloroform extractions, the samples are precipitated in two volumes of ethanol (100%) plus 1/10 volume of 5 M NaCl. This is incubated at À 20 jC for 2 h, after which it is centrifuged at 2000 Â g for 30 min at 4 jC. The pellet is then air-dried and resuspended in 200 Al of TE (10 mM Tris; 0.1 mM EDTA; pH 8.0), before storage at À 20 jC.
Detection of mutations in the CFTR gene
Amplification of CFTR exons and coding regions
Numerous PCR primers have been described for amplification of the CFTR gene. A comprehensive list of tried and tested primers currently in use can be found in a 'Table of Primers for CFTR gene Amplification' at the European Working Group on CFTR Expression website [1] . Whilst it is relatively easy to design primers to amplify a particular exon, some thought must be given to the application the PCR products are intended for. Some of the primers can be used for more than one application (e.g. sequencing, single-stranded conformational polymorphism, SSCP, etc.) but others are restricted to a specific purpose. 
Notes to '
Primers named (exon)i5 and (exon)i3 are those suggested
by Zielenski et al. [4] . These generally give a PCR product of 400-500 bases and may be used for general screening of the relevant exon. 2. Primers with the prefix 'DCF' are derived from Fanen et al. [5] and are the primers for denaturing gradient gel electrophoresis (DGGE) from that paper, less the GCclamp. These primers generally give a PCR product of a size more useful for SSCP and sequencing than the Zielenski primers [4] . 3. Primers containing the letters 'sp' have been designed especially for sequencing and are not usually used in a pair.
Mutation detection of CFTR gene by HPLC
Denaturing High Performance Liquid Chromatography (dHPLC) has been described in the past years as a method of scanning DNA samples for point mutations or variations in the genome. Initially, HPLC was a tool to separate DNA fragments as small oligonucleotides, PCR fragments, etc. The development of columns containing alkylated nonporous particles has opened a new approach to research development in the field of mutation/polymorphism detection. This technique involves subjecting PCR products to ion-pair reverse-phase liquid chromatography in a column containing alkylated non-porous particles.
Within a linear acetonitrile gradient and under partial heat denaturation, heteroduplexes (HDs) that may be present in a PCR product display a reduced column retention time compared with their counterpart wild-type (wt) homoduplexes. The pattern of profile of these HDs is in the majority of cases easily detected and additional techniques are used (such as sequencing) to confirm the presence of a mutation or sequence variation.
The list of genes studied by dHPLC as at October 2003 is available elsewhere [6] . More than 250 genes responsible for human diseases have now been totally or partially analysed by dHPLC and this technique is becoming one of the most popular for mutation scanning. The dHPLC technique has been compared to other methods with regard to sensitivity, cost and time taken to obtain the results. The conclusion of most of these studies was that dHPLC is effective, fast and sensitive for the detection of point mutations and polymorphisms. This is also our conclusion after having designed primers to enable complete scanning of the 27 exons of the CFTR gene by dHPLC. For this reason, we believe dHPLC is now the 'Gold Standard' for analysing the CFTR gene, which is one of the most highly mutated genes in the human genome.
CFTR gene analysis by SSCP
General strategy of the assay
The large size of many disease genes and the multiplicity of mutations complicate the design of an adequate assay for the identification of disease causing sequence variants. In the past 10 years, SSCP and HD analysis have rapidly gained popularity as two of the most straightforward and versatile methods to screen for DNA alterations [7] . The principle reasons for the popularity of these two methods are their technical simplicity and their high sensitivity for the detection of mutations. Traditionally, SSCP and HD are prepared separately involving timeconsuming (12 -14 h), labour-intensive, and cumbersome electrophoresis of radioactively labelled DNA samples under non-denaturing conditions in a high resolving cross-linked polyacrylamide gel and affording relatively low sensitivity of mutation detection (60 -90%) [7] . To increase sensitivity and specificity of SSCP and HD analysis, several factors have to be optimised. For SSCP analysis, these factors include: choice of gel matrix, electrophoretic conditions, presence of neutral additives, fragment size, and G + C content. For HD analysis, the principle factors influencing sensitivity are the gel matrix and the identity of the base mismatch. Thus varying these parameters, we optimised the sensitivity of our combined SSCP/HD protocol, simultaneously performing SSCP and HD analysis on the same gel and therefore increasing the sensitivity of both methods [8] . We defined uniform SSCP/ HD conditions, such as 12% (w/v) non-denaturing polyacrylamide gel, 7% (v/v) glycerol, two-phase buffer system, 90 min electrophoresis at 12 -15 jC, and silver staining. These conditions can be used for mutation screening in all 27 CFTR exons, or in any other genes. Additionally, restriction enzyme digest of the amplification product of each CFTR exon further increases mutation detection.
Screening strategy and mutation detection rate
We present a three-step screening strategy allowing analysis of the sequences with first priority within 5 h and analysis of the entire coding and adjacent noncoding regions within 1 week, including sequence analysis of the variants. The screening strategy is based on the abundance of mutations in the CFTR gene [8] . The first priority includes: exon 3, 4, 7, 10, 11, 13, 17b, 19, 20, 21 and intron 19. The second priority: exon 2, 5, 6a, 12, 14b, 15, 16, 17 and intron 11. The third priority: exon 1, 6b, 8, 9, 14a, 18, 22, 23, 24 and the promoter sequence. Many of the fragments are longer than 300 bp, but this does not seem to be a disadvantage in identifying point mutations. The reason why particular mutations can only be identified with, or without, digestion of the PCR product may be based on the fact that digestion alters the position of the sequence variant within the amplification product and in consequence also the conformation of the single-strand and/or the HD formation allowing or preventing the detection of a band shift. In our initial study, a total of 80 known CF mutations (28 missense, 22 frameshift, 17 nonsense, 13 splicesite) and 20 polymorphisms was analysed resulting in a detection rate of 97.5% including the 24 most common mutations worldwide [8] . More recently, the protocol proved to be able to detect mutations independent of their nature, frequency, and population specificity, which is also confirmed by the identification of novel mutations (i.e. 420del9, 1199delG, R560S, A613T, T1299I) in Swiss CF patients. 93 different mutations have been detected in 1200 patients analysed so far. This protocol represents a general model for point mutation analysis in genetic disorders and is successfully used for the analysis of a number of disease-causing genes. In conclusion, this protocol provides firm evidence that this SSCP/HD technique is very fast and has the ability to detect at least 97% of all sequence variants in the coding region of the CFTR gene. Thus, we consider it to be a high-yield scanning method that can be recommended to laboratories involved in the mutation screening of genetically heterogeneous populations.
Detection of F508del by ASO hybridization
The complete protocol can be used to screen for known mutations in CFTR DNA, either in genomic DNA (from patients, carriers) or in plasmids (e.g. to screen for mutants after a mutagenesis protocol). It can be found online at the European Working Group on CFTR Expression website [1] .
Two oligonucleotide probes (one complementary to the mutant sequence and another to the wt sequence in the same DNA region) should be used. Samples (PCR amplicons or plasmids) that fail to hybridize with one probe should hybridize positively with the other probe. Exceptions are amplicons from individuals who are heterozygous for the mutation under analysis. For these, positive signals (though weaker) should be seen with both probes. When a mixture of plasmids (wt and mutant) is present a similar result is obtained.
Positive controls for each sequence (acting as negative controls for the other) should always be included on the same filter as samples.
Protocol outline
After soaking the membrane first in distilled water and then into 2 Â SSC, it is assembled into the appropriate dotblot apparatus [1] . Following denaturing in appropriate solution, DNA samples under test are then applied on the membrane with the help of the three-valve system that regulates vacuum flow. Samples on apparatus wells are washed with 2 Â SSC (with vacuum off). The vacuum is turned on again and after solution absorption, the apparatus is disassembled, the membrane soaked into 2 Â SSC and air-dried, before incubation at 80 jC for 2 h for DNA fixation.
Stringent hybridization with oligonucleotidic probes 2 (radiolabelled with [g-32 P]dATP by T4 polynucleotide kinase) is carried out at 50 jC for 2 h, after overnight pre-hybridization at the same temperature. The hybridized membrane is then washed under stringent conditions (including two 30-min washes at a higher temperature) to remove unspecifically bound probe and air-dried. Before exposure to an X-ray film, with intensifying screens for 2 h at À 80 jC.
